Journey Medical Corporation Reports Full-Year 2024 Financial Results and Recent Corporate Highlights
FDA Approval of Emrosi (40 mg Minocycline Hydrochloride Modified-Release Capsules) for Rosacea Emrosi Initial Distribution Ongoing; First Prescriptions Filled Total Revenues for the Full Year Ended De ...
Family Destinations Guide5h
People Drive From All Over Ohio For The Mouth-Watering Cinnamon Rolls At This Underrated Restaurant
There’s a place in Plain City, Ohio where the cinnamon rolls are so good, they’ve achieved almost mythical status. Der ...
The Manila Times12h
Clearside Biomedical Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
Clearside's ocular oncology partner, Aura Biosciences, is enrolling patients in its global Phase 3 CoMpass trial evaluating belzupacap sarotalocan (bel-sar) for the first-line treatment of adult ...
Inhibikase Therapeutics Announces 2024 Financial Results and Highlights Recent Activity
Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company innovating small molecule kinase inhibitor therapeutics to treat pulmonary arterial ...
EQS-News: GeoVax Reports 2024 Year-End Financial Results and Provides Business Update
EQS-News: GeoVax, Inc. / Key word (s): Financial GeoVax Reports 2024 Year-End Financial Results and Provides Business Update 27.03.2025 / 21:06 CET/CEST The issuer is solely responsible for the ...
3D Systems Reports Fourth Quarter and Full Year 2024 Financial Results
D Systems Corporation (NYSE:DDD) announced today its financial results for the fourth quarter and full year ended December 31, 2024. Full-year 2024 ...